Patent ID: 8501911

Claim:
A method of decreasing MARCKS-related mucus secretion and MARCKS-related release of mediators of inflammation from infiltrating inflammatory cells in tissues of a subject in need thereof comprising: administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with an N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein, in a dual function therapeutically effective amount to reduce MARCKS-related secretion of at least one inflammatory mediator from at least one inflammatory cell in said subject and to reduce MARCKS-related mucus hypersecretion from at least one mucus secreting cell or tissue in said subject, whereby inflammation and mucus hypersecretion in said subject are reduced compared to that which would occur in the absence of said administration of said pharmaceutical composition, wherein said inflammatory mediator is secreted from an infiltrating inflammatory cell at a site of inflammation in the subject, and wherein said inflammation and mucus hypersecretion are caused by or are the clinical symptoms of a respiratory disease.